Autoimmune blistering diseases are organ-specific autoimmune conditions characterised by autoantibodies against structural skin proteins. They are divided into four main groups depending on target antigens and clinical presentation: pemphigoid diseases, pemphigus diseases—including epidermolysis bullosa acquisita (EBA)—paraneoplastic pemphigus, and dermatitis herpetiformis (DH).
Diagnosis and differentiation of autoimmune blistering diseases rely on clinical assessment combined with the detection of autoantibodies against specific target antigens.
EBA is a severe cutaneous blistering disease characterized by blister formation and autoantibodies directed against structural skin proteins—particularly type VII collagen. Histologically, eosinophils and neutrophils are observed in addition to subepidermal blisters.
Type VII collagen is a long-chain protein that anchors the basement membrane to the underlying dermal connective tissue. Autoantibodies against type VII collagen are diagnostically and pathogenetically relevant in EBA.
Serological tests support differential diagnosis, the assessment of disease activity and the progression of the disease over time.
Serum, EDTA plasma, heparin plasma, citrate plasma
ELISA
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.